Despite the importance of standardized diagnostics, there are areas across the world that do not and cannot abide by regulated processes. In low- and middle-income countries (LMICs), this can be for a multitude of reasons: lack of resources, limited training, and high costs, are just a few examples.
Respiratory diagnostics is just one area where systems are lacking. As a mild asthma patient, I’m well accustomed to spirometry and peak flow tests to check the progression of my condition. But for individuals in LMICs, this isn’t a regular opportunity. In 2023, researchers found that 95 percent of chronic obstructive pulmonary disease cases they identified were previously undiagnosed, and even when available, maintenance treatments were unaffordable.
Of course, SARS-CoV-2 had a significant effect on the world as a whole, but its damage was further exacerbated in LMICs – taking attention away from lower respiratory tract infections that are common causes of mortality in children, and further preventing improved patient care.
In our latest issue, we speak with professionals working in LMICs to identify the key unmet needs in respiratory diagnostics, and the opportunities presented with biomarker testing. Are C-reactive protein tests the path forward in respiratory diagnostics in LMICs? What role does point-of-care testing play in advancing patient care? And how do we make standardization accessible worldwide? Join the conversation: edit@thepathologist.com
Newsletters
Receive the latest analytical scientist news, personalities, education, and career development – weekly to your inbox.
References
- H Yadav et al., Lancet Glob Health, 9, 11 (2021). PMID: 34626546.
- KEH Florman et al., Am J Respir Crit Care Med, 208, 4 (2023). PMID: 37369142.
- L Frigati et al., Paediatr Respir Rev, 54 (2025). PMID: 39304357.
